Subscription pricing
Ethicist: Both ASA and TPA are clot-dissolving agents. ██████ ███████ ████ ████ ███ ████ █████████ ██████ ████ █████ ████ ██ ████ ███ ████ █████ ████ █████ ███ ███ ██ █████ ██ ███████ ████████ ██ ████ ████ ███ ███████████████ █████████████ ████████ █████ ███ █████████ ██ ███ ████████ ███ ███ ██████ ███████ ████ ████ █████ ███ ████ █████████ ████████ █████ ██ ████████████ ████████ ███ █████████ ██████ ████████ ██ █████ ███ ████ ███ ████ ████ ██ ███████ ███████ ████ ███████████████
Summarize Argument
In the choice between two medicines, there are more considerations at play than just cost vs. effectiveness. The ethicist supports this by citing that a patient’s death resulting from cost-savings would cause more grief to the patient’s family members.
Identify Conclusion
The ethicist’s conclusion insists on expanding the factors involved in a decision: “the financial saving involved in using ASA over TPA must also be weighed against such considerations.”
14.
Which one of the following ████ ██████████ █████████ ███ ██████████ ██ ███ ██████████ █████████
a
ASA should never ██ █████ ██ █████████████ ███████ ████████ ██ █████ ██ ████
b
TPA is a ████████ ████ █████████ ███████████████ █████ ████ ████
c
The extra expense ██ ███ ██████ ██ ███████ ██████ ███████ ███ ███ ██████████ █████ ██████
d
ASA is a ████ █████████ ███████████████ █████ ████ ████
e
Relatives of a ███████ ███ ███ ████ ██████ ████ ██ ███ ███████ ████████ ███ ██████ ████ ████